Compare Biogen Inc (BIIB) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Garmin Ltd. — how do they compare? Biogen Inc trades at $206.31 (market cap $30.13B), while Garmin Ltd. trades at $310.47 (market cap $59.72B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays a 1.36% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GRMN | |
|---|---|---|
Market Cap | $30.13B | $59.72B |
Sector | Health | Technology |
52-Week High | $216.63 | $313.16 |
52-Week Low | $128.93 | $187.10 |
Enterprise Value | $37.20B | $57.23B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Garmin (GRMN) trades at $310.22, down 0.94% on the day, yet maintains a bullish technical trend with strong moving averages and support near $308. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 estimate, driven by 11% revenue growth. Profitability remains high, with a net margin of 24.47% and ROE of 21.89%, though valuation multiples like P/E of 31.96 appear elevated. Recent news highlights surging fitness segment demand and a raised 2026 outlook.
Garmin's outlook is supported by consistent earnings outperformance and growth in wearable technology, but risks include rich valuations and potential sales deceleration. Analyst consensus is a $318.67 price target with a Hold-heavy rating, suggesting cautious optimism amid near-term strength. The stock's proximity to its 52-week high warrants monitoring for sustainability of momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
